Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02062203 · ClinicalTrials.gov registry record · Phase 1
Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
A Phase 1 study, sponsored by Akebia Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02062203: Completed Phase 1 study, sponsored by Akebia Therapeutics.
NCT02062203 is a Phase 1 study that has completed, run by Akebia Therapeutics. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02062203, a Phase 1 study, has completed, sponsored by Akebia Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG AKB-6548 (therapeutic dose)
- DRUG AKB-6548 (supratherapeutic dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
What the finished NCT02062203 record still lists
NCT02062203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02062203 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02062203 about?
NCT02062203 is a clinical study titled "Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers". The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.
What is the current status of trial NCT02062203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2014-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02062203?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), AKB-6548 (therapeutic dose) (DRUG), AKB-6548 (supratherapeutic dose) (DRUG).
Who is sponsoring clinical trial NCT02062203?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02062203's enrollment target sits among peer trials
50 973rd of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia